News Sentiment

CTMX sentiment intelligence

CytomX Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.01 Week of 12 Jun 2026
Weighted tone 60/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+0.3% over one week, -16.6% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 0.3% Price digesting
Trend fit Trend inactive -16.6% over four weeks
Fair value 38.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 29
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 9
simplywall.st 5
Insider Monkey 3
TradingKey 3
Simply Wall Street 3
Investing.com 3
TradingView 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 19
Deals and strategy 5
Analyst action 5
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
Stock Titan Direct company coverage

CytomX Therapeutics (CTMX) CFO sells shares to cover RSU tax withholding

CytomX Therapeutics CFO Christopher Ogden sold 1,624 shares of common stock on June 15, 2026, at an average price of $3.05 per share. This sale was a non-discretionary tax-related event to cover withholding obligations from the vesting of restricted stock units. Following the tra

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 00:40
Source
Stock Titan
Investing.com India Direct company coverage

CytomX CFO Ogden sells $4,953 in company stock By Investing.com

CytomX Therapeutics CFO Christopher Ogden sold 1,624 shares of company stock for $4,953 to cover tax obligations related to restricted stock units. Following the sale, Ogden directly holds 295,324 shares. This transaction occurs as CTMX shares are down 31% year-to-date and are co

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 00:09
Source
Investing.com India
TradingKey Direct company coverage

CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for CytomX Therapeutics Inc (CTMX). It notes that relevant data for business segments and current fiscal year quarters (FY2025, FY2025Q4, FY2025Q3, FY2025Q1) have not yet been disclosed by the company. However, it does sho

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 19:40
Source
TradingKey
Insider Monkey Direct company coverage

10 Best Growth Stocks Under $30 to Buy Now

The article highlights CytomX Therapeutics Inc. (NASDAQ: CTMX) as one of the best growth stocks under $30. It details CytomX's expanded research collaboration with Regeneron to develop next-generation bispecific cancer therapies, a deal potentially worth up to $4 billion. CytomX

Tone
Positive 72/100
Event
Deals and strategy
Published
17 Jun 2026 17:09
Source
Insider Monkey
TradingKey Direct company coverage

CytomX Therapeutics Inc (CTMX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of CytomX Therapeutics Inc (CTMX), noting its current valuation score of 7.83 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -5.63 and mentions that P/B, P/S, and P/CF data have not been di

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 09:39
Source
TradingKey
TradingKey Direct company coverage

CytomX Therapeutics Inc (CTMX) Earnings Forecast: Future EPS & Revenue Growth Estimates

CytomX Therapeutics Inc (CTMX) has an earnings forecast score of 9.00, placing it 14th in the Biotechnology & Medical Research industry. Analysts have a "Strong Buy" rating with an average price target of $6.50. The company's expected revenue for the next quarter is $12.31M, with

Tone
Positive 73/100
Event
Earnings
Published
17 Jun 2026 08:39
Source
TradingKey
Stocktwits Direct company coverage

CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside

Following positive early-stage trial data for its lead asset Varseta-M in metastatic colorectal cancer, CytomX Therapeutics (CTMX) has received multiple price target revisions from analysts. Jefferies raised its price target to $16-$18, indicating a potential upside of up to 230%

Tone
Positive 75/100
Event
Analyst action
Published
09 Jun 2026 22:39
Source
Stocktwits
MarketBeat Direct company coverage

Schulhoff & Co. Inc. Acquires Shares of 374,850 CytomX Therapeutics, Inc. $CTMX

Schulhoff & Co. Inc. has acquired a new stake of 374,850 shares in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the fourth quarter, valued at approximately $1.6 million. This investment highlights broader institutional interest, with hedge funds and other institutional investor

Tone
Positive 66/100
Event
Earnings
Published
08 Jun 2026 14:09
Source
MarketBeat
TradingView Direct company coverage

CTMX: Varseta-M shows strong efficacy in late-line CRC, with pivotal trials and new partnerships advancing

CytomX Therapeutics (CTMX) has made significant progress with its Probody platform and expanded its collaboration with Regeneron, securing substantial funding. Their drug Varseta-M has shown strong efficacy and a manageable safety profile in advanced colorectal cancer, with pivot

Tone
Positive 75/100
Event
Market update
Published
04 Jun 2026 20:10
Source
TradingView
Simply Wall Street Direct company coverage

CytomX Therapeutics (Nasdaq:CTMX) - Stock Analysis

CytomX Therapeutics (CTMX) is an oncology-focused biopharmaceutical company with a market cap of US$692.3m. The stock is considered 70.0% undervalued by analysts and its revenue is forecast to grow 37.37% per year, despite being currently unprofitable. Recent updates include posi

Tone
Neutral 50/100
Event
Earnings
Published
04 Jun 2026 12:08
Source
Simply Wall Street
MSN Direct company coverage

CytomX gains as licensing deal with Regeneron expands

CytomX Therapeutics saw its shares rise following an expanded licensing agreement with Regeneron Pharmaceuticals. The deal builds on a collaboration initiated in 2021, focusing on the development of bispecific anticancer therapeutics using CytomX's Probody platform. Under the new

Tone
Positive 72/100
Event
Deals and strategy
Published
03 Jun 2026 16:41
Source
MSN
The Globe and Mail Direct company coverage

CytomX (CTMX) Q4 2025 Earnings Transcript

CytomX Therapeutics announced positive Phase I dose expansion data for Varseta-M in late-line colorectal cancer patients, showing strong anti-tumor activity with confirmed overall response rates of 32% and 20% at its highest dose levels. The company has made significant progress

Tone
Positive 76/100
Event
Earnings
Published
02 Jun 2026 18:10
Source
The Globe and Mail
Insider Monkey Direct company coverage

Wolfe Research Initiates Coverage of CytomX Therapeutics (CTMX) with Outperform

Wolfe Research initiated coverage of CytomX Therapeutics (CTMX) with an Outperform rating and a $6 price target, citing the company's de-risked EpCAM antibody-drug conjugate. Separately, H.C. Wainwright lowered its price target to $11 from $17, maintaining a Buy rating due to dil

Tone
Positive 64/100
Event
Analyst action
Published
22 May 2026 14:41
Source
Insider Monkey
The Manila Times Direct company coverage

CytomX Therapeutics to Present at Upcoming June Investor Conferences

CytomX Therapeutics announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, which focuses on devel

Tone
Positive 64/100
Event
Market update
Published
21 May 2026 11:40
Source
The Manila Times
Stock Titan Direct company coverage

Cytomx Therapeutics in June investor events at Jefferies, Goldman Sachs

CytomX Therapeutics (Nasdaq: CTMX) announced its management will participate in two investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 4th and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10th. The company's management will

Tone
Neutral 50/100
Event
Market update
Published
21 May 2026 11:40
Source
Stock Titan
Moomoo Direct company coverage

Wolfe Research Initiates CytomX Therapeutics With Outperform Rating

Wolfe Research has initiated coverage of CytomX Therapeutics with an Outperform rating. This indicates a positive outlook from the research firm regarding the pharmaceutical company's stock performance.

Tone
Positive 70/100
Event
Analyst action
Published
19 May 2026 16:38
Source
Moomoo
Investing.com Direct company coverage

Wolfe Research initiates CytomX stock with outperform rating

Wolfe Research has initiated coverage on CytomX Therapeutics (NASDAQ:CTMX) with an outperform rating and a $3.50 price target, citing promising results from its Varseta-M drug candidate in metastatic colorectal cancer. The company has several catalysts expected within the next 12

Tone
Positive 74/100
Event
Analyst action
Published
19 May 2026 11:09
Source
Investing.com
Investing.com Direct company coverage

CytomX appoints Mamata Gokhale as regulatory affairs head

CytomX Therapeutics has appointed Mamata Gokhale, Ph.D., RAC, as its Senior Vice President of Regulatory Affairs. Dr. Gokhale will lead the company's global regulatory strategy, bringing over 25 years of experience in the field. The company, focused on cancer treatments, reported

Tone
Positive 67/100
Event
Regulatory and legal
Published
18 May 2026 12:39
Source
Investing.com
TipRanks Direct company coverage

CytomX’s CX-801 Enters Key Early Cancer Trial Phase, Putting CTMX Back on Investor Radar

CytomX Therapeutics (CTMX) announced that its experimental cancer drug, CX-801, has entered a key early-phase clinical trial (CTMX-801-101) for advanced solid tumors. The study, conducted alone and in combination with Merck's Keytruda, aims to assess safety, dosage, and initial a

Tone
Positive 71/100
Event
Market update
Published
16 May 2026 02:39
Source
TipRanks
Stock Titan Direct company coverage

Venrock group files Amendment reporting 9.98M CTMX shares (NASDAQ: CTMX)

A Venrock-related group has filed an Amendment to Schedule 13G/A, disclosing beneficial ownership of 9,982,124 shares of CytomX Therapeutics (NASDAQ: CTMX) common stock as of March 31, 2026, representing a 4.6% stake. This stake is split among Venrock Healthcare Capital Partners

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Perceptive (CTMX) reports 10,098,824 shares, a 4.6% stake

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund collectively reported beneficial ownership of 10,098,824 shares of CytomX Therapeutics (CTMX) common stock, representing a 4.6% stake. This information was disclosed in an amended Schedule 13G/A SEC fil

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 19:39
Source
Stock Titan